Education Alert
Expert-Driven, Patient-Focused: Mastering Personalized Care for HER2-Low Metastatic Breast Cancer
0.25 CPD
What's really the difference between HER2-negative and HER2-low disease? See how this distinction impacts real treatment decisions.

Updates in Prostate Cancer

FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels

JANX007 Displays Encouraging Safety/Efficacy in Metastatic CRPC

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

CLINICAL ADVANCES IN Management of Lung Cancer

Supported by an independent educational grant from F. Hoffman-La Roche Ltd.

New Resources are now available from Medscape Education’s Clinical Advances in The Management of Lung Cancer.

NEW Conference Insights: Breaking Developments in ALK-Positive NSCLC and ES-SCLC
Are you staying up to date on the latest practice-changing data revolutionizing the treatment for lung cancer?

Advances in Lung Cancer Management
Face off against your colleagues in a fast-paced series of medical questions about lung cancer! Deepen knowledge, have fun, and grapple for the number 1 spot on the leaderboard.

Related Resources
Access relevant clinical articles, guidelines, and downloadable slides.

Clinical Advances in The Management of Lung Cancer is a thematic curriculum for physicians, dedicated to improving the management of patients with lung cancer. 

Steering Committee
 

公告: 台灣臨床進階教育基金會_血液腫瘤藥學論壇數位課程資訊 課程報名連結： https://tace.xms.tw/succession/show/22 上課說明 1.     本系列課程共3個主題10堂課程。 2.     上課對象：藥師、西醫師、護理師、專科護理師，或對此主題有興趣的醫事人員。 3.     提供藥師、西醫師、 護理師、專科護理師繼續教育積分，每堂課1積分，積分屬性請至各課程查詢。 4.     每堂課程收費100元，台灣血液腫瘤藥學會會員免費上課。 5.     各堂課程需完成課程測驗(考試成績須達80分)、課程閱讀指定時間期滿及課程回饋問卷，即可取得繼續教育積分。 6.     每月10號上傳教育積分。 7.     上課時間：即日起至2026年12月31日。
 

BREAKING NEWS Data from the phase 1/2 GO29781 trial led to the approval of subcutaneous mosunetuzumab in R/R follicular lymphoma after 2 or more lines of prior therapy. 
 

Data from the phase 3 PALOMA-3 study support the approval of subcutaneous amivantamab in this NSCLC population.

Findings from the phase 3 TRITON3 trial evaluating rucaparib in adult patients with metastatic BRCA-mutated CRPC supported the regulatory decision.